Skip to content
value.today

Carmot Therapeutics Inc.

Total raised
$349 M
5 rounds on record
Latest round
$150 M
May 2023
First round on record
Apr 2010
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Carmot Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$150 MNo. 5$50 to $250 million

Carmot Therapeutics Inc.: Raise no. 5, May 2023

Investors in this round

25 investors had bought by the notice of Jun 6, 2023: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Carmot Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$150 M of $150 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Heather K. Turner · Executive Officer, Director
  • Aetna Wun K. Trombley · Director
  • Anne K. Phillips, M.D. · Director
  • Peter K. Svennilson · Director
  • Stig K. Hansen, Ph.D. · Director
  • Tim K. Kutzkey · Director
  • Timothy K. Garnett · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Heather Turner, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 6, 2023. Read the notice at the SEC.

equitySEC
Jul 2022$161 MNo. 4$50 to $250 million

Carmot Therapeutics Inc.: Raise no. 4, Jul 2022

Investors in this round

15 investors had bought by the notice of Aug 8, 2022: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Carmot Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$161 M of $161 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stig K. Hansen · Executive Officer, Director
  • Aetna Wun K. Trombley · Director
  • Peter K. Svennilson · Director
  • Tim K. Kutzkey · Director
  • Timothy K. Garnett · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stig K. Hansen, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 8, 2022. Read the notice at the SEC.

equitySEC
Sep 2020$26 MNo. 3$10 to $50 million

Carmot Therapeutics Inc.: Raise no. 3, Sep 2020

Investors in this round

6 investors had bought by the notice of Oct 1, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Carmot Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $47 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stig K. Hansen · Executive Officer, Director
  • Aetna Wun K. Trombley · Director
  • Peter K. Svennilson · Director
  • Tim K. Kutzky · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stig K. Hansen, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 1, 2020. Read the notice at the SEC.

equitySEC
Aug 2017$11 MNo. 2$10 to $50 million

Carmot Therapeutics Inc.: Raise no. 2, Aug 2017

Investors in this round

4 investors had bought by the notice of Aug 25, 2017: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Carmot Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $15 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel A. Erlanson · Executive Officer, Director
  • Stig K. Hansen · Executive Officer, Director
  • Aetna Wun Trombley · Director
  • Larry K. Lasky · Director
  • Tim K. Kutzkey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stig K. Hansen, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 25, 2017. Read the notice at the SEC.

equitySEC
Apr 2010$2 MNo. 1Under $2 million

Carmot Therapeutics Inc.: Raise no. 1, Apr 2010

Investors in this round

2 investors had bought by the notice of Apr 23, 2010: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Carmot Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel A. Erlanson · Executive Officer, Director
  • Stig K. Hansen · Executive Officer, Director
  • Magnus K. Persson · Director
  • Tim K. Kutzkey · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stig K. Hansen, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 23, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Carmot Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2023).

    SEC Form D · Jun 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2023

That is all the official record says: Carmot Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Carmot Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Franklin Biotechnology Discovery FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, Jul 2026)SEC Form N-PORT

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 25 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Carmot Therapeutics Inc.
NameRoleNamed in
Heather K. TurnerExecutive officerJun 2023
Stig K. HansenExecutive officerAug 2022
Daniel A. ErlansonExecutive officerAug 2017
Aetna Wun K. TrombleyDirectorJun 2023
Anne K. Phillips, M.D.DirectorJun 2023
Heather K. TurnerDirectorJun 2023
Peter K. SvennilsonDirectorJun 2023
Stig K. Hansen, Ph.D.DirectorJun 2023
Tim K. KutzkeyDirectorJun 2023
Timothy K. GarnettDirectorJun 2023
Stig K. HansenDirectorAug 2022
Tim K. KutzkyDirectorOct 2020
Aetna Wun TrombleyDirectorAug 2017
Daniel A. ErlansonDirectorAug 2017
Larry K. LaskyDirectorAug 2017
Magnus K. PerssonDirectorApr 2010

About

Company in San Francisco, United States.